Hexarelin: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข4 community protocols documented
- โขEvidence level: Anecdotal Reports
- โขBased on 60 community reports
- โข3 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Receptor Desensitization | Published studies show hexarelin causes significant GH response desensitization with repeated dosing. Phase 2 trials documented reduced GH output over 12-16 weeks of continuous use. | Community uses strict cycling protocols (8-12 weeks on, 4-6 weeks off) to manage desensitization. This is a key differentiator from ipamorelin, which is believed to cause less desensitization. | high Hexarelin desensitization is one of the best-documented clinical findings among GHRPs. Community cycling protocols are a direct response to this published data. |
| Dual Receptor Activity | Published research demonstrates hexarelin binds both GHS-R1a (ghrelin receptor) and CD36 (scavenger receptor), with CD36-mediated cardioprotective effects independent of GH release. | Community is primarily interested in GH release. Some users are aware of the cardioprotective CD36 binding but this is not a primary motivator for most hexarelin users. | moderate The dual receptor profile is a unique feature of hexarelin. The CD36-mediated cardioprotective effects do not require GH release and may persist even after GHS-R1a desensitization. |
| Potency and Side Effects | Clinical data shows hexarelin as among the most potent GH secretagogues tested, with significant cortisol, prolactin, and ACTH elevation. | Community considers hexarelin the most potent commonly available GHRP but recommends it only for experienced users due to cortisol and prolactin elevation and desensitization risk. | moderate Community caution about hexarelin is well-aligned with clinical data. It is generally recommended as a later-stage peptide for users who have experience with ipamorelin or GHRP-2. |
Compare these community approaches with published research findings.
Community Protocols
Standard GH Release Protocol
Popular- Route
- Subcutaneous
- Dose
- 100-200 mcg
- Frequency
- 2-3 times daily
- Duration
- 8-12 weeks with mandatory 4-6 week break
Most potent common GHRP; requires strict cycling to prevent receptor desensitization. Injected on empty stomach.
Tolerance Assessment Protocol
Common- Route
- Subcutaneous
- Dose
- 100 mcg
- Frequency
- Once daily
- Duration
- First 1-2 weeks
Starting dose for tolerance assessment before titrating up; used to gauge individual response and side effects
Hexarelin + GHRH Combination
Common- Route
- Subcutaneous
- Dose
- 100 mcg hexarelin + 100 mcg Mod GRF 1-29
- Frequency
- 2-3 times daily
- Duration
- 8-12 weeks
Maximum GH release combination; considered the most potent GHRP + GHRH stack but with most side effects
Cardioprotective Protocol
Niche- Route
- Subcutaneous
- Dose
- 100-200 mcg
- Frequency
- Once daily
- Duration
- 8-12 weeks
Lower-dose protocol targeting hexarelin CD36 receptor binding for cardiac health; less focused on GH release
Stacking Patterns
Hexarelin + CJC-1295 No DAC
CommonMaximum-potency GH secretagogue stack; hexarelin as the most potent GHRP combined with GHRH for synergistic release
Hexarelin + Sermorelin
NichePotent GHRP with FDA-approved GHRH analog; some users prefer sermorelin for its established safety profile when using a potent GHRP
Hexarelin Rotation with Ipamorelin
NicheAlternating potent and selective GHRPs to balance maximum GH release with reduced desensitization risk; hexarelin for training days, ipamorelin for rest days
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 60+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Reddit r/Peptides|Hexarelin experience reports and desensitization discussions(accessed 2026-02-16)
- Reddit r/PeptideResearch|Hexarelin protocol and cycling discussions(accessed 2026-02-16)
- Peptide Initiative|Hexarelin Dosing Protocols (complete dosing guide)(accessed 2026-02-16)
- Peptide Initiative|Hexarelin Patient Education (safe and effective use guide)(accessed 2026-02-16)
- Wikipedia|Hexarelin (Examorelin) pharmacology overview(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for Hexarelin (Examorelin). The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.
Hexarelin is considered the most potent commonly available GHRP in the peptide community. Its unique dual receptor activity (GHS-R1a for GH release and CD36 for cardioprotection) and its documented desensitization profile make it a distinctive peptide in the GH secretagogue category.
Understanding Protocol Divergence#
Desensitization Management#
The most significant community concern with hexarelin is receptor desensitization. Unlike ipamorelin, which is believed to cause minimal desensitization, hexarelin shows documented GH response reduction with continued use. Community cycling protocols are a direct response to this clinical finding and represent one of the few areas where community practice is directly informed by published clinical data.
Cardioprotective Potential#
Hexarelin's binding to the CD36 receptor is a unique feature not shared by other GHRPs. While the community primarily uses hexarelin for GH release, some users are aware of the cardioprotective potential. Notably, CD36-mediated effects may persist even after GHS-R1a desensitization, as they operate through an independent pathway.
Commonly Reported Outcomes#
Community members frequently report the following when using hexarelin:
- Strong GH response: Perceived as more potent than ipamorelin or GHRP-2 for acute GH release
- Rapid desensitization: Reduced perceived effects after 8-12 weeks of continuous use
- Cortisol effects: Some users report symptoms consistent with elevated cortisol (water retention, mood changes)
- Sleep quality: Improved sleep depth, particularly when dosed before bed
- Tingling/numbness: Transient tingling in extremities shortly after injection
Important Caveats#
- Desensitization is well-documented and requires cycling
- Cortisol and prolactin elevation are more pronounced than with selective GHRPs
- Generally recommended only for experienced GHRP users
- Product quality varies between vendors
Reconstitution and Storage Practices#
- Reconstitution: 1-2 mL bacteriostatic water per 5 mg vial
- Storage: Refrigerated at 2-8 degrees C after reconstitution
- Shelf life: Use within 3-4 weeks of reconstitution
- Injection volume: Typically 0.02-0.1 mL per injection
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Hexarelin
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.